Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17



2559 items
1:17 PM, Sep 07, 2018  |  BioCentury | Strategy

Thinking beyond Bi

Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there...
6:27 PM, Aug 03, 2018  |  BioCentury | Strategy

Addressing sexual harassment claims at the board level

In today’s environment, no industry is immune from claims of workplace harassment. Allegations can not only tarnish a company’s -- and a board’s -- reputation, and impair shareholder value, but imperil the existence of a...
2:52 PM, Jul 13, 2018  |  BioCentury | Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
5:51 PM, Jun 22, 2018  |  BioCentury | Strategy

Gawande’s Cheesecake Factory

Details about the healthcare organization Atul Gawande will run for Inc., Berkshire Hathaway Inc. and J. P. Morgan Chase & Co. are scarce -- basic facts, starting with its name, have not been disclosed....
7:35 PM, Jun 19, 2018  |  BioCentury | Strategy

Channel your outrage

Before the dust settles on the PABNAB debacle, save some outrage for what really matters: not the periodic stripper party that screams “sickening,” but the entrenched attitudes and daily affronts that end up keeping women...
10:29 PM, Jun 01, 2018  |  BioCentury | Strategy

Partnering on a mission

With a $260 million war chest and a banner roster of execs, advisors and deals, Brii Biosciences is pushing an agenda to bring infectious diseases to the forefront of innovation in China. Its top priority...
3:55 PM, May 11, 2018  |  BioCentury | Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
7:59 PM, May 04, 2018  |  BioCentury | Strategy

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
5:46 PM, Apr 27, 2018  |  BioCentury | Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...
6:23 PM, Mar 30, 2018  |  BioCentury | Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...